Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma-Reference-Cited by-同舟云学术

Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

Published:2020-03-18 Issue:5 Volume:14 Page:964-973
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Urup Thomas¹²^ORCID,Gillberg Linn³⁴,Kaastrup Katja³⁴,Lü Maya Jeje Schuang¹,Michaelsen Signe Regner¹,Andrée Larsen Vibeke⁵,Christensen Ib Jarle⁶,Broholm Helle⁷,Lassen Ulrik¹²,Grønbæk Kirsten³⁴,Poulsen Hans Skovgaard¹²

Affiliation:

1. Department of Radiation Biology Centre for Cancer and Organ Diseases Rigshospitalet Copenhagen Denmark

2. Department of Oncology Centre for Cancer and Organ Diseases Rigshospitalet Copenhagen Denmark

3. Department of Hematology Centre for Cancer and Organ Diseases Rigshospitalet Copenhagen Denmark

4. Biotech Research and Innovation Centre (BRIC) Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

5. Department of Radiology Center of Diagnostic Investigation Rigshospitalet Copenhagen Denmark

6. Department of Gastroenterology Hvidovre Hospital Hvidovre Denmark

7. Department of Neuropathology Center of Diagnostic Investigation Rigshospitalet Copenhagen Denmark

Funder

Kræftens Bekæmpelse

I.M. Daehnfeldt Foundation

Rigshospitalet

Genentech

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12660

Reference31 articles.

1. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation

2. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas

3. The transcriptional network for mesenchymal transformation of brain tumours

4. The Tumor Microenvironment Strongly Impacts Master Transcriptional Regulators and Gene Expression Class of Glioblastoma

5. Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glioma and Peptidergic Systems: Oncogenic and Anticancer Peptides;International Journal of Molecular Sciences;2024-07-22

2. Upregulation of the Renin–Angiotensin System Is Associated with Patient Survival and the Tumour Microenvironment in Glioblastoma;Cells;2024-04-05

3. DNA methylation heterogeneity attributable to a complex tumor immune microenvironment prompts prognostic risk in glioma;Epigenetics;2024-03-05

4. Deep DNA sequencing of MGMT, TP53 and AGT in Mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker;Journal of Neuro-Oncology;2022-12-16

5. Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?;Journal of the College of Physicians and Surgeons Pakistan;2021-08-01